At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine ...
The Nova 301 Phase 3 trial is a randomized, observer-blind, placebo-controlled trial evaluating the efficacy, safety and immunogenicity of mRNA-1403. The trial aims to enroll approximately 25,000 ...
GlobalData on MSN26d
Moderna’s norovirus vaccine enters Phase III trials in the UKA Phase III clinical trial is being launched in the UK to investigate Moderna’s norovirus vaccine mRNA-1403. This is the ...
The first, an investigational norovirus mRNA vaccine from Moderna (mRNA-1403), safely elicited strong antibody responses in adults against globally prevalent norovirus genotypes, according to ...
Zacks.com on MSN1mon
MRNA Begins Dosing in Pivotal Study on Norovirus VaccineModerna, Inc. MRNA announced the dosing of the first participant in the phase III Nova 301 study, which is evaluating its ...
The Nova 301 phase 3 trial is a randomized, observer-blind, placebo-controlled trial evaluating the efficacy, safety and immunogenicity of mRNA-1403. The trial aims to enroll approximately 25,000 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback